Stocks and Investing
Stocks and Investing
Mon, January 23, 2017
[ 09:46 AM ] - United States, WOPRAI
[ 09:46 AM ] - United States, WOPRAI
[ 09:46 AM ] - United States, WOPRAI
[ 09:46 AM ] - United States, WOPRAI
[ 09:46 AM ] - United States, WOPRAI
[ 09:45 AM ] - United States, WOPRAI
[ 09:45 AM ] - United States, WOPRAI
[ 09:45 AM ] - United States, WOPRAI
[ 09:45 AM ] - United States, WOPRAI
[ 09:45 AM ] - United States, WOPRAI
[ 09:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 12:45 AM ] - United States, WOPRAI
[ 12:45 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Kennen MacKay Initiated (BMRN) at Buy with Decreased Target to $107 on, Jan 23rd, 2017
Kennen MacKay of Credit Suisse, Initiated "BioMarin Pharmaceutical Inc." (BMRN) at Buy with Decreased Target from $111 to $107 on, Jan 23rd, 2017.
Kennen has made no other calls on BMRN in the last 4 months.
There are 3 other peers that have a rating on BMRN. Out of the 3 peers that are also analyzing BMRN, 2 agree with Kennen's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Gena Wang of "Barclays" Downgraded from Buy to Hold and Decreased Target to $105 on, Tuesday, November 29th, 2016
- Christopher Raymond of "Piper Sandler" Downgraded from Buy to Hold on, Monday, November 7th, 2016
This is the rating of the analyst that currently disagrees with Kennen
- Andrew Peters of "Deutsche Bank" Initiated at Strong Buy on, Thursday, November 3rd, 2016
Contributing Sources